Download Files:
Products Details
Product Description
– Zicronapine is an antipsychotic medication with a strong pro-cognitive effect in animal models and the potential to treat a number of neurological and psychiatric diseases. Zicronapine has potent antagonistic effects at dopamine D1/D2, and serotonin 5-HT2A receptors.
Web ID
– HY-14827
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C22H27ClN2
References
– [1]Lopez De Diego, Heidi. et al. Succinate and malonate salts of trans-4-(1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and their preparation, pharmaceutical compositions, and use as medicaments, particularly as antipsychotics. WO2005016900A1|[2]Lundbeck H. A/S. The clinical phase III programme commenced on zicronapine. 20 Jan 2011.|[3]Lundbeck H, A/S. Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia –planning for continued clinical work. Press release No. 392 18 December 2009.
CAS Number
– 170381-16-5
Molecular Weight
– 354.92
SMILES
– CC1(C)N(C)CCN([C@@H]2C[C@@H](C3=CC=CC=C3)C4=C2C=C(Cl)C=C4)C1
Clinical Information
– Phase 3
Research Area
– Neurological Disease
Solubility
– 10 mM in DMSO
Target
– 5-HT Receptor;Dopamine Receptor
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
